Wouter W de Herder

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi request reprint Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
    Wouter W de Herder
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Eur J Endocrinol 155:717-23. 2006
  2. ncbi request reprint Dopamine receptor expression and function in corticotroph pituitary tumors
    Rosario Pivonello
    Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:2452-62. 2004
  3. ncbi request reprint Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly
    Wouter W de Herder
    Section of Endocrinology, Department of Internal Medicine, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Endocrinol 153:67-71. 2005
  4. pmc Acromegaly and gigantism in the medical literature. Case descriptions in the era before and the early years after the initial publication of Pierre Marie (1886)
    Wouter W de Herder
    Department of Internal Medicine, Sector of Endocrinology, Erasmus MC, 3015 CE Rotterdam, The Netherlands
    Pituitary 12:236-44. 2009
  5. pmc Acromegalic gigantism, physicians and body snatching. Past or present?
    Wouter W de Herder
    Department of Internal Medicine, Sector of Endocrinology, Erasmus MC, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    Pituitary 15:312-8. 2012
  6. pmc Familial gigantism
    Wouter W de Herder
    Department of Internal Medicine, Sector of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Clinics (Sao Paulo) 67:29-32. 2012
  7. ncbi request reprint Somatostatin receptors in pheochromocytoma
    Wouter W de Herder
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Front Horm Res 31:145-54. 2004
  8. ncbi request reprint Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours
    W W de Herder
    Department of Internal Medicine, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Endocr Relat Cancer 10:451-8. 2003
  9. ncbi request reprint Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas
    W W de Herder
    Department of Internal Medicine Section of Endocrinology, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Endocr Relat Cancer 11:19-34. 2004
  10. ncbi request reprint Somatostatin analogs as radiodiagnostic tools
    Wouter W de Herder
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam
    Rev Endocr Metab Disord 6:23-7. 2005

Detail Information

Publications135 found, 100 shown here

  1. ncbi request reprint Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
    Wouter W de Herder
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Eur J Endocrinol 155:717-23. 2006
    ..We have studied the correlation between in vivo imaging of D2 receptors using (123)I-epidepride and the radiological response of NFPA to DA in 18 patients...
  2. ncbi request reprint Dopamine receptor expression and function in corticotroph pituitary tumors
    Rosario Pivonello
    Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:2452-62. 2004
    ..The effectiveness of cabergoline in normalizing cortisol secretion in 40% of cases supports its therapeutic use in the management of Cushing's disease...
  3. ncbi request reprint Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly
    Wouter W de Herder
    Section of Endocrinology, Department of Internal Medicine, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Endocrinol 153:67-71. 2005
    ..To study whether the growth hormone (GH) response after the subcutaneous administration 50 microg of octreotide (acute octreotide test) has any predictive value for long-term IGF-I normalization with Sandostatin LAR...
  4. pmc Acromegaly and gigantism in the medical literature. Case descriptions in the era before and the early years after the initial publication of Pierre Marie (1886)
    Wouter W de Herder
    Department of Internal Medicine, Sector of Endocrinology, Erasmus MC, 3015 CE Rotterdam, The Netherlands
    Pituitary 12:236-44. 2009
    ..The stage was set for further research into the pathogenesis, diagnosis and therapy of acromegaly and gigantism...
  5. pmc Acromegalic gigantism, physicians and body snatching. Past or present?
    Wouter W de Herder
    Department of Internal Medicine, Sector of Endocrinology, Erasmus MC, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    Pituitary 15:312-8. 2012
    ..The case-histories of these 6 patients and also the circumstances that led to the (in-) voluntary donation of their bodies are reviewed...
  6. pmc Familial gigantism
    Wouter W de Herder
    Department of Internal Medicine, Sector of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Clinics (Sao Paulo) 67:29-32. 2012
    ..Familial GH-secreting tumors are seen in association with three separate hereditary clinical syndromes: multiple endocrine neoplasia type 1, Carney complex, and familial isolated pituitary adenomas...
  7. ncbi request reprint Somatostatin receptors in pheochromocytoma
    Wouter W de Herder
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Front Horm Res 31:145-54. 2004
  8. ncbi request reprint Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours
    W W de Herder
    Department of Internal Medicine, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Endocr Relat Cancer 10:451-8. 2003
    ..Currently, [(111)In-DTPA(0)]octreotide, [(90)Y-DOTA(0),Tyr(3)]octreotide, [(177)Lu-DOTA(0)Tyr(3)]octreotate, [(111)In-DOTA(0)]lanreotide and [(90)Y-DOTA(0)]lanreotide can be used for this purpose...
  9. ncbi request reprint Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas
    W W de Herder
    Department of Internal Medicine Section of Endocrinology, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Endocr Relat Cancer 11:19-34. 2004
    ..The delicate balance of the use of the different therapeutical options in patients with endocrine tumours of the gastrointestinal tract and pancreas emphasizes the importance of team approach and team expertise...
  10. ncbi request reprint Somatostatin analogs as radiodiagnostic tools
    Wouter W de Herder
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam
    Rev Endocr Metab Disord 6:23-7. 2005
  11. ncbi request reprint Insulinoma
    W W de Herder
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Neuroendocrinology 80:20-2. 2004
    ..In patients with metastatic insulinomas, symptoms of insulin hypersecretion will only completely disappear after complete resection of all metastases...
  12. ncbi request reprint [Giantism. A historical and medical view]
    W W de Herder
    Erasmus Medisch Centrum, afd Inwendige Geneeskunde, sector Endocrinologie, Dr Molewaterplein 40, 30o5 GD Rotterdam
    Ned Tijdschr Geneeskd 148:2585-90. 2004
    ..In the western world, it is unlikely that there will be many more people with fully developed giantism due to the current high level of medical care...
  13. ncbi request reprint Diagnostic imaging of dopamine receptors in pituitary adenomas
    Wouter W de Herder
    Departments of Internal Medicine and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Eur J Endocrinol 156:S53-6. 2007
    ..Dopamine D2 receptors on pituitary tumours can also be studied using positron emission tomography with (11)C-N-raclopride and (11)C-N-methylspiperone...
  14. ncbi request reprint Biochemistry of neuroendocrine tumours
    Wouter W de Herder
    Department of Internal Medicine, Sector of Endocrinology, Erasmus MC, 3015 CE Rotterdam, The Netherlands
    Best Pract Res Clin Endocrinol Metab 21:33-41. 2007
    ..Among the tumour-non-specific markers are: chromogranins, neuron-specific enolase (NSE), alpha-subunits of the glycoprotein hormones, catecholamines, pancreatic polypeptide (PP), ghrelin and adrenomedullin...
  15. ncbi request reprint Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome)
    W W de Herder
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Best Pract Res Clin Gastroenterol 19:705-15. 2005
    ..In inoperable patients, biotherapy with somatostatin analogues and interferon-alpha is the treatment of choice. Somatostatin analogues and interferon-alpha significantly improve symptoms...
  16. ncbi request reprint Well-differentiated pancreatic tumor/carcinoma: insulinoma
    Wouter W de Herder
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Neuroendocrinology 84:183-8. 2006
  17. ncbi request reprint Neuroendocrine tumors and somatostatin: imaging techniques
    W W de Herder
    Section of Endocrinology, Department of Internal Medicine, Erasmus Rotterdam, The Netherlands
    J Endocrinol Invest 28:132-6. 2005
    ..A large variety of lesions in and around the pituitary region express somatostatin receptors and, therefore, can be visualized by 111In-pentetreotide scintigraphy...
  18. ncbi request reprint Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors
    Wouter W de Herder
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Endocrine 20:285-90. 2003
    ..Radiotherapy with octapeptide somatostatin analogs coupled to radionuclides such as indium-111, yttrium-90, and lutetium- 177 is currently being studied in phase I-III trials...
  19. ncbi request reprint Clinical endocrinology and metabolism. Gut endocrine tumours
    W W de Herder
    Erasmus University Rotterdam, Rotterdam, Netherlands
    Best Pract Res Clin Endocrinol Metab 18:477-95. 2004
    ..A team approach is needed to achieve a balanced opinion on the use of the different therapeutic options in patients with these tumours...
  20. ncbi request reprint Somatostatin receptor imaging for neuroendocrine tumors
    Wouter W de Herder
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Pituitary 9:243-8. 2006
    ..However, a large variety of lesions in and around the pituitary region also express somatostatin receptors and, therefore, can be visualized by (111)In-pentetreotide scintigraphy...
  21. ncbi request reprint New therapeutic options for metastatic malignant insulinomas
    Wouter W de Herder
    Department of Internal Medicine, Sector of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 75:277-84. 2011
    ..With the introduction of these new therapeutic modalities, the therapeutic arsenal for the 'tailor-made' approach of patients with metastatic insulinomas is further expanded...
  22. doi request reprint Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Endocr Relat Cancer 17:R53-73. 2010
    ..If more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable GEPNETs...
  23. ncbi request reprint Expression of activin and inhibin subunits, receptors and binding proteins in human pheochromocytomas: a study based on mRNA analysis and immunohistochemistry
    J Hofland
    Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 66:335-40. 2007
    ..So far, one of the few reported markers to discriminate malignant from benign tumours is the betaB-subunit of inhibin and activin, members of the transforming growth factor (TGF)-beta superfamily of growth and differentiation factors...
  24. ncbi request reprint Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors
    L J Hofland
    Department of Internal Medicine III, Erasmus University, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 82:3011-8. 1997
    ..However, in the majority of NFAs and prolactinomas, DA-agonists were equally or more effective than SS in the suppression of tumoral secretion products...
  25. doi request reprint Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Clin Oncol 26:2124-30. 2008
    ..Here we report on the toxicity and efficacy of this treatment, performed in over 500 patients...
  26. ncbi request reprint The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5
    Leo J Hofland
    Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Centre, GD Rotterdam, The Netherlands
    Eur J Endocrinol 152:645-54. 2005
    ..We compared the in vitro effects of the sst(2)-preferring SS analogue octreotide (OCT) and the multi-ligand SOM230 on ACTH release by human and mouse corticotroph tumour cells...
  27. ncbi request reprint Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas
    L J Hofland
    Department of Internal Medicine III, Erasmus University, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 84:3336-43. 1999
    ....
  28. pmc Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 35:743-8. 2008
    ..Adding capecitabine to (177)Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now present the short-term toxicity profile of this novel combination...
  29. doi request reprint Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy
    Diego Ferone
    Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 93:1412-7. 2008
    ..In nine cases, GH and PRL content was further studied by immunoelectron microscopy...
  30. doi request reprint The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells
    Maria Cristina De Martino
    Division of Endocrinology, Department of Internal Medicine, Room Ee530b, Erasmus MC, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Endocr Relat Cancer 19:351-64. 2012
    ..mTOR could be a target for the treatment of human ACCs, but variable responses might be expected. In selected cases of ACC, the combined targeting of mTOR and IGF2 could have greater effects than mTOR inhibitors alone...
  31. doi request reprint Biochemical predictors of outcome of pituitary surgery for Cushing's disease
    R A Alwani
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Centre, Rotterdam, The Netherlands
    Neuroendocrinology 91:169-78. 2010
    ..The aims of this retrospective study were twofold: (i) investigate early and late results of TS for CD, and (ii) evaluate various postoperative tests in order to predict the outcome of TS...
  32. doi request reprint Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane
    Peter M van Koetsveld
    Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, Erasmus MC, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Endocr Relat Cancer 20:443-54. 2013
    ..The inhibition of the expression of steroidogenic enzymes by IFN-β is a novel mechanism that may explain its inhibitory effect on cortisol production...
  33. ncbi request reprint The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients
    Joost van der Hoek
    Department of Internal Medicine, Section Endocrinology, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 63:176-84. 2005
    ..c. injection SOM230 100 and 250 microg, were compared to those following OCT 100 microg...
  34. ncbi request reprint Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate
    Kimberly Kamp
    Sector of Endocrinology, Department of Internal Medicine Department of Nuclear Medicine, Erasmus Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands Centro de Oncologia, Hospital Sirio Libanes, Sao Paulo, Brazil Department of Pathophysiology, National University of Athens, Athens, Greece
    Endocr Relat Cancer 20:825-31. 2013
    ..1 vs 11.4 months) and shorter when compared with the RADIANT-1 trial (13.1 vs 16.7 months). In conclusion, the safety profile of everolimus is not influenced by previous treatment with peptide receptor radiotherapy...
  35. ncbi request reprint Hypocalcaemia after treatment with [177Lu-DOTA 0,Tyr3]octreotate
    Esther I van Vliet
    Department of Nuclear Medicine, Erasmus MC, University Medical Center, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 40:1843-52. 2013
    ..The aim of this study was to explore the possible mechanisms involved in an observed decline in serum calcium levels in patients with a neuroendocrine tumour (NET) treated with [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate)...
  36. pmc Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
    Bart de Keizer
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 35:749-55. 2008
    ..The aim of this study was to investigate the incidence of hormonal crises after therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate)...
  37. doi request reprint Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells
    Giovanni Vitale
    Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    Am J Physiol Endocrinol Metab 296:E559-66. 2009
    ....
  38. ncbi request reprint The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro
    Leo J Hofland
    Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:1577-85. 2004
    ..Second, compared with OCT, SOM230 is more potent in inhibiting PRL release by mixed GH/PRL-secreting adenoma and prolactinoma cells...
  39. pmc Effects of therapy with [177Lu-DOTA 0,Tyr 3]octreotate on endocrine function
    Jaap J M Teunissen
    Department of Nuclear Medicine, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 36:1758-66. 2009
    ..We determined the effects of PRRT with [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate) on glucose homeostasis and the pituitary-gonadal, pituitary-thyroid and pituitary-adrenal axes...
  40. ncbi request reprint Dopamine receptor expression and function in corticotroph ectopic tumors
    Rosario Pivonello
    Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 92:65-9. 2007
    ..Dopamine receptor (DR) expression and dopamine agonist (DA) effectiveness have never been demonstrated in neuroendocrine tumors associated with ectopic ACTH syndrome (EAS)...
  41. doi request reprint Medical therapy of acromegaly: efficacy and safety of somatostatin analogues
    Richard A Feelders
    Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
    Drugs 69:2207-26. 2009
    ....
  42. ncbi request reprint Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 34:1219-27. 2007
    ..As patients with foregut carcinoids may respond differently, we here present the effects of this treatment in a subgroup of patients with foregut carcinoids of bronchial, gastric or thymic origin...
  43. pmc Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate
    Flavio Forrer
    Department of Nuclear Medicine, Erasmus MC Rotterdam, Dr Molewaterplein 40, NL 3015 GD, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 36:1138-46. 2009
    ..Also, we evaluated the absorbed cross-dose from the source organs (liver, spleen, kidneys and blood), tumours and the so-called "remainder of the body" to the bone marrow...
  44. ncbi request reprint Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth
    Peter M van Koetsveld
    Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 91:4537-43. 2006
    ..Despite efforts to develop new therapeutic regimens for metastatic ACC, surgery remains the mainstay of treatment. Interferons are known to exert tumor-suppressive effects in several types of human cancer...
  45. doi request reprint Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Endocrinol Metab Clin North Am 40:173-85, ix. 2011
    ..Overall survival is several years from diagnosis. These data compare favorably with the limited number of alternative treatments. If more widespread use of PRRT can be guaranteed, such therapy may become the therapy of first choice...
  46. doi request reprint Peptide receptor radionuclide therapy (PRRT) for GEP-NETs
    Hendrik Bergsma
    Department of Nuclear Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Best Pract Res Clin Gastroenterol 26:867-81. 2012
    ..Considering the mild side-effects, PRRT may well become the first-line therapy in patients with metastasised or inoperable GEP-NETs if more widespread use of PRRT can be accomplished...
  47. pmc Lutetium-labelled peptides for therapy of neuroendocrine tumours
    B L R Kam
    Department of Nuclear Medicine, Erasmus MC, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 39:S103-12. 2012
    ..If more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable neuroendocrine tumours...
  48. doi request reprint Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly
    Federico Gatto
    Department of Internal Medicine, Erasmus MC, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 98:E66-71. 2013
    ..Recently, a new rabbit monoclonal anti-sst2A antibody (clone UMB-1) has been validated as a reliable method to selectively detect sst2A protein levels in formalin-fixed tissues...
  49. ncbi request reprint Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy
    Eric P Krenning
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 46:76S-82S. 2005
    ....
  50. doi request reprint Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Semin Nucl Med 40:78-88. 2010
    ..If more widespread use of peptide receptor radionuclide therapy can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable gastroenteropancreatic neuroendocrine tumors...
  51. doi request reprint Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy
    E Van Schaik
    Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 96:3381-9. 2011
    ..Only 10% are considered malignant. Control of insulin hypersecretion and hypoglycemia in patients with malignant insulinomas may be extremely difficult. Different medications and chemotherapy schedules have been used...
  52. doi request reprint Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients
    S J C M M Neggers
    Department of Medicine, Erasmus University, Erasmus MC, Rotterdam, The Netherlands
    Eur J Endocrinol 160:529-33. 2009
    ..We previously reported on the efficacy, safety, and quality of life (QoL) of long-acting somatostatin analogs (SSA) and (twice) weekly pegvisomant (PEG-V) in acromegaly and improvement after the addition of PEG-V to long-acting SSA...
  53. ncbi request reprint Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly
    Sebastian J C M M Neggers
    Department of Internal Medicine, Erasmus University MC Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 92:4598-601. 2007
    ..We previously reported the efficacy of a combined treatment of active acromegaly with both long-acting somatostatin analogs (SSA) and pegvisomant (PEG-V)...
  54. ncbi request reprint Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, Netherlands
    J Clin Oncol 23:2754-62. 2005
    ..Chemotherapy can be effective, but the response is usually less than 1 year. Here, we present the results of treatment with a radiolabeled somatostatin analog, [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate)...
  55. doi request reprint Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma
    Ilse G C Hermsen
    Department of Internal Medicine, Maxima Medical Centre, PO Box 90052, 5600 PD Eindhoven, The Netherlands
    Eur J Endocrinol 169:51-8. 2013
    ..The epidermal growth factor receptor (EGFR) has been implicated in the development of one-third of all malignancies. EGFR pathway members in ACC have been investigated, however, without available clinical data and relation to survival...
  56. doi request reprint Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    J Nucl Med 51:383-90. 2010
    ..We present the effects of additional therapy with (177)Lu-octreotate in patients in whom progressive disease developed after an initial benefit from regular therapy...
  57. doi request reprint Regulation of steroidogenesis in a primary pigmented nodular adrenocortical disease-associated adenoma leading to virilization and subclinical Cushing's syndrome
    Johannes Hofland
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Eur J Endocrinol 168:67-74. 2013
    ..Mutations in the cAMP protein kinase A regulatory subunit type 1A (PRKAR1A) are causative of PPNAD. Steroidogenesis in PPNAD can be modified through a local glucocorticoid feed-forward loop...
  58. doi request reprint Melanocortin 2 receptor-associated protein (MRAP) and MRAP2 in human adrenocortical tissues: regulation of expression and association with ACTH responsiveness
    Johannes Hofland
    Department of Internal Medicine, Erasmus Medical Center, Room Ee 532, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 97:E747-54. 2012
    ..MC2R trafficking and signaling are dependent on the MC2R accessory protein (MRAP). The MRAP homolog MRAP2 also transports the MC2R to the cell surface but might prevent activation...
  59. doi request reprint Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant
    S J C M M Neggers
    Department of Internal Medicine, Erasmus University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 93:3853-9. 2008
    ....
  60. pmc Somatostatin analogue treatment of neuroendocrine tumours
    W W de Herder
    Department of Internal Medicine III, University Hospital, Rotterdam, Netherlands
    Postgrad Med J 72:403-8. 1996
    ..Long-term therapy with somatostatin analogues of catecholamine-secreting (malignant) paragangliomas and phaeochromocytomas has not shown clinical benefits...
  61. ncbi request reprint Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 47:1599-606. 2006
    ..Here we present the effects of this therapy in a small number of patients with metastasized or inoperable paragangliomas, meningiomas, small cell lung carcinomas (SCLCs), and melanomas...
  62. ncbi request reprint Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues
    Dik J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Hematol Oncol Clin North Am 21:561-73; x. 2007
    ..Also, if kidney-protective agents are used, the side effects of this therapy are few and mild. These data compare favorably with the limited number of alternative treatment approaches...
  63. ncbi request reprint Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney
    Edgar J Rolleman
    Department of Nuclear Medicine, Erasmus MC, Room L244, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 34:1854-60. 2007
    ..In the human kidney, somatostatin receptors are expressed in the vasa recta, tubuli and glomeruli. It is not clear to what extent these receptors contribute to the total kidney radioactivity uptake...
  64. ncbi request reprint The 'bio-assay' quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations
    Ingrid E Bonapart
    Department of Endocrinology, Erasmus Medical Centre, University Hospital of Rotterdam, Rotterdam, The Netherlands
    Eur J Endocrinol 152:217-24. 2005
    ..To investigate the quality of life (QoL) in acromegalic patients in relation to biochemical parameters...
  65. doi request reprint Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas
    Christiaan de Bruin
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 94:1118-24. 2009
    ..To what extent these receptor subtypes are coexpressed within individual adenomas, is not known however...
  66. ncbi request reprint IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro
    Giovanni Vitale
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Cancer Res 66:554-62. 2006
    ..Further studies are required to establish whether IFN-beta has comparable potent tumor growth inhibitory effects in vivo...
  67. ncbi request reprint Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma
    Esther Korpershoek
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center Rotterdam, JNI room 222, PO Box 2040, 3000 CR Rotterdam, The Netherlands
    Endocr Relat Cancer 14:453-62. 2007
    ..We suggest that sequential mutation analysis should be directed first at RET, followed by VHL and SDHD for patients with bilateral adrenal PCC at diagnosis, and at SDHB and SDHD for patients with sPGL...
  68. pmc Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion
    C de Bruin
    Department of Internal Medicine, Erasmus Medical Center, Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 97:455-62. 2012
    ..Follow-up octreoscans after, respectively, 6 and 12 months showed the unequivocal presence of a bronchial carcinoid in both patients...
  69. ncbi request reprint In vitro secretion of FSH by cultured clinically nonfunctioning and gonadotroph pituitary adenomas is directly correlated with locally produced levels of activin A
    H T Wessels
    Department of Endocrinology and Reproduction, Erasmus University Rotterdam, Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 54:485-92. 2001
    ..Since many of the NFAs and Gn-omas secrete FSH in vitro, we hypothesized that locally produced activin may stimulate secretion of FSH in these pituitary adenomas...
  70. ncbi request reprint Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma
    F R Nobels
    Department of Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Eur J Endocrinol 143:615-21. 2000
    ....
  71. ncbi request reprint Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels
    R A Feelders
    Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 90:6480-9. 2005
    ..It is not exactly known when patients with acromegaly should be evaluated for cure after transsphenoidal adenomectomy (TA)...
  72. ncbi request reprint Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant
    J Feenstra
    Department of Internal Medicine, Edocrinology Unit, Erasums Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Eur J Endocrinol 154:805-6. 2006
    ..Clinicians should be aware of this potential severe adverse drug reaction and therefore frequent control of hepatic enzymes is mandatory during treatment with pegvisomant...
  73. pmc ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase
    Johannes Hofland
    Department of Internal Medicine, Section of Endocrinology, P, O, Box 2040, Rotterdam, CA, 3000, The Netherlands
    Orphanet J Rare Dis 8:142. 2013
    ..We investigated the prevalence of adrenocortical reactions to these stimuli in a large cohort of AIMAH patients, both in vivo and in vitro...
  74. ncbi request reprint An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis
    Francien H van Nederveen
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, Netherlands
    Lancet Oncol 10:764-71. 2009
    ..We investigated whether SDHB immunohistochemistry could effectively discriminate between SDH-related and non-SDH-related phaeochromocytomas and paragangliomas in large retrospective and prospective tumour series...
  75. pmc Endoscopic bilateral adrenalectomy in patients with ectopic Cushing's syndrome
    Wijnand J Alberda
    Department of Surgery, Erasmus Medical Center, University Medical Center Rotterdam, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    Surg Endosc 26:1140-5. 2012
    ..ECS patients have an increased risk for complications, because of high cortisol levels, poor clinical condition, and metabolic disturbances. This study aims to evaluate the safety and long-term efficacy of endoscopic BLA for ECS...
  76. pmc Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate
    D J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 30:417-22. 2003
    ..However, in view of the high success rate of therapy with (177)Lu-octreotate and the absence of serious side-effects, we advocate its use in patients with GEP tumours without waiting for tumour progression...
  77. doi request reprint The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy
    R van der Pas
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Centre, Room Ee 569, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 97:1303-10. 2012
    ..Cushing's disease (CD) is accompanied by an increased risk of venous thromboembolism. Surgery is the primary treatment of CD...
  78. ncbi request reprint The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas
    N D Bouvy
    Department of Surgery, Josephine Nefkens Institute, Erasmus MC University Medical Centre, Rotterdam, The Netherlands
    Histopathology 51:239-45. 2007
    ..To compare two different multiparameter histopathological scoring indices and determine their prognostic value in patients presenting with adrenocortical carcinoma (ACC)...
  79. ncbi request reprint [Cushing's syndrome. II. New forms of treatment]
    M O van Aken
    Erasmus MC, afd Inwendige Geneeskunde, sectie Endocrinologie, kamer H 496, Postbus 2040, 3000 CA Rotterdam
    Ned Tijdschr Geneeskd 150:2365-9. 2006
    ..The primary treatment for ACTH-independent Cushing's syndrome is laparoscopic adrenalectomy. In rare cases of bilateral adrenal hyperplasia, medicinal treatment aimed at new regulatory pathways of cortisol secretion can be applied...
  80. doi request reprint Risk Factors for Hemodynamic Instability during Surgery for Pheochromocytoma
    H Bruynzeel
    Erasmus Medical Center, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 95:678-85. 2010
    ..Efficacy for preventing HD instability was identical for PXB and DOX...
  81. ncbi request reprint Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases?
    E van der Harst
    Department of Surgery, Erasmus University Hospital, Rotterdam, The Netherlands
    J Pathol 191:175-80. 2000
    ..The predictive value of S100 immunostaining, tumour size, and extra-adrenal location of the tumour was also confirmed...
  82. ncbi request reprint Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly
    J Feenstra
    Department of Internal Medicine, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, Netherlands
    Lancet 365:1644-6. 2005
    ..This combined treatment is effective, might increase compliance, and could greatly reduce the costs of medical treatment for acromegaly in some patients...
  83. ncbi request reprint A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients
    Joost van der Hoek
    Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:638-45. 2004
    ..We conclude that SOM230 is an effective GH-lowering drug in acromegalic patients with the potential to increase the number of patients controlled during long-term medical treatment...
  84. pmc Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
    Sebastian J C M M Neggers
    Department of Medicine, Erasmus University Medical Center Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
    Pituitary 14:253-8. 2011
    ..However, there seems to be a wide variation in the reduction of PEG-V dose, which can be obtained after conversion to combined treatment...
  85. doi request reprint Pituitary tumours: the sst/D2 receptors as molecular targets
    Leo J Hofland
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
    Mol Cell Endocrinol 326:89-98. 2010
    ..In this review the current knowledge on the expression and functional roles of sst and D2 in pituitary tumours is discussed...
  86. ncbi request reprint Octreoscan radioreceptor imaging
    Aart J van der Lely
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Endocrine 20:307-11. 2003
    ..The value of somatostatin receptor imaging in patients with other tumors, like breast cancer, or in patients with granulomatous diseases, has to be established...
  87. ncbi request reprint Adult hyperinsulinemic hypoglycemia not caused by an insulinoma: a report of two cases
    B C van der Wal
    Department of Surgery, Erasmus University Hospital, Rotterdam, The Netherlands
    Virchows Arch 436:481-6. 2000
    ..In infantile nesidioblastosis, a proportion of cases has been associated with mutations in one of several genes. Whether such mutations, leading to hyperinsulinism, also play a role in adult nesidioblastosis is presently unknown...
  88. doi request reprint Rapid decrease in adrenal responsiveness to ACTH stimulation after successful pituitary surgery in patients with Cushing's disease
    R A Alwani
    Department of Internal Medicine, Endocrine Section, Erasmus Medical Centre, Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 75:602-7. 2011
    ..The aim of this study was to investigate the effects of transsphenoidal surgery (TS) on the adrenal sensitivity to ACTH (adrenocorticotropin) stimulation in patients with Cushing's disease (CD)...
  89. doi request reprint Phaeochromocytomas and sympathetic paragangliomas
    B J Petri
    Department of Pathology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands
    Br J Surg 96:1381-92. 2009
    ..Surgical resection is the treatment of choice for both PCC and sPGL, but controversy exists about the management of patients with bilateral or multiple tumours...
  90. doi request reprint Fluconazole inhibits human adrenocortical steroidogenesis in vitro
    R van der Pas
    Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Endocrinol 215:403-12. 2012
    ..Furthermore, patients receiving fluconazole because of mycosis might be at risk for developing adrenocortical insufficiency...
  91. doi request reprint 5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients
    S C van Dijk
    Department of Internal Medicine, Sector of Endocrinology, Erasmus MC, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Bone 50:1260-5. 2012
    ..In conclusion, the current study in a unique group of untreated carcinoid patients could not demonstrate a major role for circulating serotonin in the control of bone metabolism...
  92. ncbi request reprint Decreased ligand affinity rather than glucocorticoid receptor down-regulation in patients with endogenous Cushing's syndrome
    N A Huizenga
    Department of Internal Medicine III, Dijkzigt University Hospital Rotterdam, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Endocrinol 142:472-6. 2000
    ..The mechanisms of action of GCs are mediated by the intracellular glucocorticoid receptor (GR). Over the years, many studies have been performed concerning the regulation of GR expression by GC concentrations...
  93. ncbi request reprint [Growth hormone receptor antagonists: potential indications]
    A F Muller
    Erasmus Universitair Medisch Centrum, afd Inwendige Geneeskunde, Dr Molewaterplein 40, 3015 GD Rotterdam
    Ned Tijdschr Geneeskd 145:69-73. 2001
    ..Animal studies in which human colon and breast cancer models were used showed that pegvisomant can powerfully decrease tumour growth. Studies in cancer patients have not yet started...
  94. doi request reprint Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study
    D J F Stuijver
    Department of Internal Medicine, Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
    J Clin Endocrinol Metab 96:3525-32. 2011
    ..Venous thrombosis has frequently been reported in patients with endogenous Cushing's syndrome (CS)...
  95. ncbi request reprint A risk-benefit assessment of octreotide in the treatment of acromegaly
    A J van der Lely
    Department of Internal Medicine, University Hospital Dijkzigt, Erasmus University, Rotterdam, The Netherlands
    Drug Saf 17:317-24. 1997
    ..Desensitisation to the beneficial effects of octreotide therapy is highly unusual. A long-acting formulation of octreotide is being studied, and should be available by the end of 1997...
  96. ncbi request reprint [Adrenal incidentaloma: a clinical problem related to imaging]
    E L E de Bruijne
    afd Inwendige Geneeskunde, Erasmus MC, Rotterdam
    Ned Tijdschr Geneeskd 149:1821-6. 2005
    ..The exact nature of the defect is often unclear and further evaluation is required to determine functionality and possible malignancy. An algorithm is presented for the management of adrenal incidentalomas...
  97. ncbi request reprint Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience
    Roelf Valkema
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Semin Nucl Med 32:110-22. 2002
    ..The decrease in serum inhibin B and concomitant increase of serum FSH levels in men indicate that the spermatogenesis was impaired...
  98. ncbi request reprint Somatostatin and somatostatin analogues: diagnostic and therapeutic uses
    Wouter W de Herder
    Division of Endocrinology, Department of Internal Medicine, University Hospital, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Curr Opin Oncol 14:53-7. 2002
    ..Radiolabeled octapeptide analogues can also be used for radiotherapy of sst 2 - and sst 5 -positive advanced or metastatic neuroendocrine tumors...
  99. ncbi request reprint A postcard of a giant and his physician (collection W.W. de Herder)
    W W de Herder
    Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
    J Endocrinol Invest 28:392. 2005
  100. ncbi request reprint The value of plasma markers for the clinical behaviour of phaeochromocytomas
    E van der Harst
    Department of Surgery, Erasmus University Hospital and MCRZ location Clara, Rotterdam, The Netherlands
    Eur J Endocrinol 147:85-94. 2002
    ..This study intends to define predictive plasma markers for their variable postoperative behaviour. Furthermore, the diagnostic accuracy of these plasma tests was determined...